MX2015005949A - Nucleosidos que contienen aza-azucar antiviral. - Google Patents
Nucleosidos que contienen aza-azucar antiviral.Info
- Publication number
- MX2015005949A MX2015005949A MX2015005949A MX2015005949A MX2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A
- Authority
- MX
- Mexico
- Prior art keywords
- azasugar
- compounds
- viral
- pharmaceutically acceptable
- antiviral
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 2
- 108020000999 Viral RNA Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000029812 viral genome replication Effects 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727468P | 2012-11-16 | 2012-11-16 | |
| PCT/US2013/070537 WO2014078778A2 (en) | 2012-11-16 | 2013-11-18 | Antiviral azasugar-containing nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005949A true MX2015005949A (es) | 2015-09-08 |
Family
ID=50731836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005949A MX2015005949A (es) | 2012-11-16 | 2013-11-18 | Nucleosidos que contienen aza-azucar antiviral. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150291596A1 (enExample) |
| EP (2) | EP3251674A3 (enExample) |
| JP (1) | JP2016504284A (enExample) |
| AU (1) | AU2013344422A1 (enExample) |
| CA (1) | CA2890905A1 (enExample) |
| HK (1) | HK1212235A1 (enExample) |
| IL (1) | IL238785A0 (enExample) |
| MX (1) | MX2015005949A (enExample) |
| WO (1) | WO2014078778A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130862T1 (hr) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| UA111163C2 (uk) | 2010-07-22 | 2016-04-11 | Гайлід Сайєнсіз, Інк. | Способи й сполуки для лікування вірусних інфекцій paramyxoviridae |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| MA52371A (fr) * | 2015-09-16 | 2021-09-22 | Gilead Sciences Inc | Méthodes de traitement d'infections dues aux coronaviridae |
| TW201725203A (zh) | 2015-12-16 | 2017-07-16 | 必治妥美雅史谷比公司 | 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| CN106834546A (zh) * | 2017-03-20 | 2017-06-13 | 杭州迪安医学检验中心有限公司 | 一种基于熔解曲线法单管同时检测多种呼吸道病毒的引物及其应用 |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| ES3000461T3 (en) | 2017-07-11 | 2025-02-28 | Gilead Sciences Inc | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN109053788A (zh) * | 2018-09-20 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种吡唑类化合物的制备方法 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202532084A (zh) | 2020-05-29 | 2025-08-16 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| CN111704619B (zh) * | 2020-07-30 | 2021-10-19 | 四川大学 | 一种Forodesine的制备方法 |
| PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN114588159A (zh) * | 2020-12-07 | 2022-06-07 | 成都傲科新技术有限责任公司 | 一种治疗猫冠状病毒感染的化合物及其应用 |
| JPWO2022270628A1 (enExample) * | 2021-06-25 | 2022-12-29 | ||
| PE20240654A1 (es) * | 2021-08-20 | 2024-04-04 | Shionogi & Co | Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral |
| CN113666941B (zh) * | 2021-09-01 | 2023-03-10 | 浙江珲达生物科技有限公司 | 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP0630904A4 (en) * | 1992-08-26 | 1995-01-04 | Japan Tobacco Inc. | Novel nicotine derivative. |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| AU2003233667A1 (en) * | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| EP1544294B8 (en) * | 2002-07-17 | 2014-03-19 | Riken | Nucleosides or nucleotides having novel unnatural bases and use thereof |
| WO2004050676A1 (ja) | 2002-12-04 | 2004-06-17 | Mitsubishi Gas Chemical Company, Inc. | フッ素化方法 |
| US6780993B1 (en) * | 2003-02-19 | 2004-08-24 | Biocryst Pharmaceuticals, Inc. | Preparation of deazaguanine analog |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| US7560434B2 (en) * | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| KR20070100237A (ko) * | 2004-10-29 | 2007-10-10 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | 치료용 푸로피리미딘 및 티에노피리미딘 |
| DK1891038T3 (da) * | 2005-05-13 | 2009-01-19 | Lilly Co Eli | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
| CA2618335C (en) * | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| EP1951244A4 (en) * | 2005-11-22 | 2010-08-25 | Glaxosmithkline Llc | CALCILYTIC COMPOUNDS |
| MX2008007103A (es) | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
| US7829584B2 (en) | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| US8030322B2 (en) | 2006-04-27 | 2011-10-04 | Glaxo Group Limited | Spirocompounds useful as modulators for dopamine D3 receptors |
| SG177974A1 (en) * | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| CA2685520A1 (en) * | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| EP2348854A4 (en) * | 2008-09-22 | 2012-03-14 | Einstein Coll Med | METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING |
| WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
| WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
| EP2627334B1 (en) * | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2013
- 2013-11-18 EP EP17162146.9A patent/EP3251674A3/en not_active Withdrawn
- 2013-11-18 AU AU2013344422A patent/AU2013344422A1/en not_active Abandoned
- 2013-11-18 EP EP13855441.5A patent/EP2919785A4/en not_active Withdrawn
- 2013-11-18 JP JP2015542870A patent/JP2016504284A/ja active Pending
- 2013-11-18 CA CA2890905A patent/CA2890905A1/en not_active Abandoned
- 2013-11-18 HK HK16100301.6A patent/HK1212235A1/xx unknown
- 2013-11-18 MX MX2015005949A patent/MX2015005949A/es unknown
- 2013-11-18 WO PCT/US2013/070537 patent/WO2014078778A2/en not_active Ceased
- 2013-11-18 US US14/441,762 patent/US20150291596A1/en not_active Abandoned
-
2015
- 2015-05-13 IL IL238785A patent/IL238785A0/en unknown
-
2017
- 2017-03-31 US US15/475,507 patent/US20170267681A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013344422A1 (en) | 2015-07-02 |
| WO2014078778A2 (en) | 2014-05-22 |
| US20170267681A1 (en) | 2017-09-21 |
| WO2014078778A3 (en) | 2014-10-09 |
| US20150291596A1 (en) | 2015-10-15 |
| CA2890905A1 (en) | 2014-05-22 |
| JP2016504284A (ja) | 2016-02-12 |
| EP2919785A2 (en) | 2015-09-23 |
| EP2919785A4 (en) | 2016-10-05 |
| EP3251674A2 (en) | 2017-12-06 |
| HK1212235A1 (en) | 2016-06-10 |
| EP3251674A3 (en) | 2018-02-21 |
| IL238785A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| MX2013008359A (es) | Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana. | |
| GEP201706698B (en) | Inhibitors of influenza viruses replication | |
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| TN2013000421A1 (en) | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| WO2010084115A3 (en) | Antiviral agents | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| MX363270B (es) | Composiciones y metodos para inhibir la polimerasa viral. | |
| BR112014027117A2 (pt) | derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson | |
| WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
| EP2583962A4 (en) | NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug | |
| MX350516B (es) | Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2. | |
| WO2012169863A3 (en) | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии | |
| WO2015036898A3 (en) | Novel salts of crizotinib and their preparation | |
| TR201005911A2 (tr) | Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu. |